ReviewOncology letters2024

Biomarkers to predict the benefits of immune‑checkpoint blockade‑based therapy in patients with malignant peritoneal mesothelioma (Review).

Chunhong Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.